Regensburg, November 14, 2007 - GENEART AG, the world’s leading producer of synthetic genes and specialist in the field of synthetic biology, continued its growth trend in net sales and earnings in the first nine months and in the third quarter of 2007.GENEART has advanced the production of synthetic genes to an industrial level. This step by step replaces older, time and cost-intensive genetic engineering methods, some of which have been in use for as many as 30 years. Owing to the new technologies, GENEART AG has become a more and more important R&D partner in the pharmaceutical, chemical and biotechnology industry, as well as for public research institutions. Clear indicators of this positive trend are the GENEART AG net sales figures, which have increased in the first nine months of the current business year from Euro 5.7M to Euro 9.0M. Relative to the same period in the previous year, this is an increase of 57 %. Relative to total revenues, the GENEART AG grew by 105 percent in the first nine months and even by a whopping 136 percent in the third quarter.
